Intuitive's FDA Inquiry: Nightmare or Noise?

While Intuitive Surgical shares have bounced back from Thursday's late day sell-off, investors are still left with more questions than they have answers. In the following video, Brenton Flynn outlines yesterday's news and provides one reason to be optimistic around the outcome of this FDA inquiry. In the spirit of balance, he also offers one fact that gives him pause about investing in the stock.

Are stories of Intuitive's demise greatly exaggerated?
Recently, some investors have questioned Intuitive Surgical's future. However, Intuitive Surgical expert Karl Thiel believes a visible path to long-term growth persists. Will Intuitive capitalize, or be crushed by unforeseen pitfalls? His report highlights all of the key opportunities and risks facing the company -- and includes a full year of ongoing updates as key new hits -- so be sure to claim your copy by clicking here now.

The article Intuitive's FDA Inquiry: Nightmare or Noise? originally appeared on Fool.com.

Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Intuitive Surgical. The Motley Fool owns shares of Intuitive Surgical and Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.